Literature DB >> 30198923

Perioperative Considerations for Evolving Artificial Pancreas Devices.

Micah T Long1, Douglas B Coursin1,2, Mark J Rice3.   

Abstract

Type 1 diabetes mellitus is a lifelong condition. It requires intensive patient involvement including frequent glucose measurements and subcutaneous insulin dosing to provide optimal glycemic control to decrease short- and long-term complications of diabetes mellitus without causing hypoglycemia. Variations in insulin pharmacokinetics and responsiveness over time in addition to illness, stress, and a myriad of other factors make ideal glucose control a challenge. Control-to-range and control-to-target artificial pancreas devices (closed-loop artificial pancreas devices [C-APDs]) consist of a continuous glucose monitor, response algorithm, and insulin delivery device that work together to automate much of the glycemic management for an individual while continually adjusting insulin dosing toward a glycemic target. In this way, a C-APD can improve glycemic control and decrease the rate of hypoglycemia. The MiniMed 670G (Medtronic, Fridley, MN) system is currently the only Food and Drug Administration-cleared C-APD in the United States. In this system, insulin delivery is continually adjusted to a glucose concentration, and the patient inputs meal-time information to modify insulin delivery as needed. Data thus far suggest improved glycemic control and decreased hypoglycemic events using the system, with decreased need for patient self-management. Thus, the anticipated use of these devices is likely to increase dramatically over time. There are limited case reports of safe intraoperative use of C-APDs, but the Food and Drug Administration has not cleared any device for such use. Nonetheless, C-APDs may offer an opportunity to improve patient safety and outcomes through enhanced intraoperative glycemic control. Anesthesiologists should become familiar with C-APD technology to help develop safe and effective protocols for their intraoperative use. We provide an overview of C-APDs and propose an introductory strategy for intraoperative study of these devices.

Entities:  

Year:  2019        PMID: 30198923     DOI: 10.1213/ANE.0000000000003779

Source DB:  PubMed          Journal:  Anesth Analg        ISSN: 0003-2999            Impact factor:   5.108


  3 in total

Review 1.  [Treatment of diabetes mellitus in perioperative medicine-an update].

Authors:  B Rupprecht; A Stöckl; S Stöckl; C Dietrich
Journal:  Anaesthesist       Date:  2020-11-03       Impact factor: 1.041

Review 2.  Developing Insulin Delivery Devices with Glucose Responsiveness.

Authors:  Zejun Wang; Jinqiang Wang; Anna R Kahkoska; John B Buse; Zhen Gu
Journal:  Trends Pharmacol Sci       Date:  2020-11-26       Impact factor: 14.819

Review 3.  Neuromodulation of metabolic functions: from pharmaceuticals to bioelectronics to biocircuits.

Authors:  Benjamin J Seicol; Sebastian Bejarano; Nicholas Behnke; Liang Guo
Journal:  J Biol Eng       Date:  2019-08-01       Impact factor: 4.355

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.